AbbVie to Buy Immunology Drugmaker Apogee for $10.9 Billion
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"AbbVie to Buy Immunology Drugmaker Apogee for $10.9 Billion" is generating significant coverage in the Business category, with 4 articles from 4 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Whalesbook, GuruFocus, RAPS.org and The Business Journals. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 50d ago.
Quick answers
Why is "AbbVie to Buy Immunology Drugmaker Apogee for $10.9 Billion" trending?
Because 4 independent news sources published 4 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (11)
- AbbVie paying $10.9B to buy Waltham biotech NBC Boston · 50d ago
- 3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal Yahoo Finance · 50d ago
- Why AbbVie Is Spending $11 Billion to Buy Apogee Therapeutics—and Why the Stock Is Rising Barron's · 50d ago
- AbbVie Goes On The Offensive With $10.9 Billion Takeover Investor's Business Daily · 50d ago
- AbbVie sharpens immunology focus with $10.9 billion Apogee deal Reuters · 50d ago
- AbbVie to buy Waltham’s Apogee Therapeutics in nearly $11 billion deal The Boston Globe · 50d ago
- Done deal: AbbVie to buy Apogee for $10.9B FirstWord Pharma · 50d ago
- US Stocks Steady Near Record Highs; AbbVie to Buy Apogee for $10.9 Billion Whalesbook · 50d ago
- AbbVie's $10.9 Billion Apogee Deal Joins a $200 Billion Pharma Spree GuruFocus · 50d ago
- Recon: AbbVie forges $10.9 billion deal with Apogee; US FDA changes tack on Regenxbio's rare disease gene therapy RAPS.org · 50d ago
- AbbVie seals $10.9 billion deal to acquire biotech Apogee Therapeutics The Business Journals · 50d ago
Topics
Related trends
Scientists discover what may be behind Alzheimer’s
New research into brain immune cell turnover around age fifty provides unprecedented clues regarding the progression of Alzheimer's disease.
Do Altered Immune Cells Drive Skin Cancer in Immunosuppressed Patients?
4 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Best Buy’s back-to-school sale takes up to 50% off laptops, ANC headphones and more
5 news sources are covering this Technology story right now — PULSE is tracking how fast it spreads.
Study of lung immune cells uncovers roots of autoimmune disease - news-medical.net
Recent scientific research explores how human lung immune cells protect against infections and potentially drive autoimmune disease.
A simple supplement could help the immune system fight cancer and viruses
6 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Sandisk: Looking Like A Buy Ahead Of Earnings (NASDAQ:SNDK)
SanDisk shares experience market turbulence and intense scrutiny across financial platforms ahead of upcoming earnings reports.